In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

Derisking the Development of Sensitive Injectables
Webinars, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions

Helping Pharma Manufacturers Meet New Annex 1 Requirements
Publications, Pharmaceutical, Market Insights, Product Solutions

Advanced Parenteral Closure Solutions: The Perfect Fit Towards Compliance with EMA GM...
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Exploring Extractable and Leachable Testing Strategies for Parenterals
Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions